

**Prevalence and factors affecting
opposition of insulin initiation among
type2 DM patients at Ain Shams
University hospitals**

Thesis

*Submitted for Partial Fulfillment of Master Degree
in Family Medicine*

By

Eman Mostafa Ahmed

Master degree in Family Medicine

Under supervision of

Prof. Essam Mohammed Bayoumy Helal

Professor of Internal Medicine

Faculty of Medicine – Ain Shams University

Prof. Daa Marzouk Abdel Hamid

Head of Family Medicine Department

Faculty of Medicine – Ain Shams University

Dr. Maha Magdy Mahmoud Wahdan

Lecturer of Epidemiology - Community Department

Faculty of Medicine – Ain Shams University

Faculty of Medicine - Ain Shams University

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Essam Mohammed Bayoumy Helal**, Professor of Internal Medicine - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dina Marzouk Abdel Hamid**, Head of Family Medicine Department, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Maha Magdy Mahmoud Wahdan**, Lecturer of Epidemiology - Community Department, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Eman Mostafa Ahmed

List of Contents

Title	Page No.
List of Tables	4
List of Figures.....	8
List of Abbreviations	9
Introduction	1
Aim of the Work	6
Review of Literature	
▪ Epidemiology of Diabetes Mellitus	7
▪ Role of Insulin in Type 2 Diabetes Mellitus	16
▪ Psychological Insulin Resistance	22
Patients and Methods.....	43
Results	52
Discussion.....	96
Conclusion	135
Recommendations	136
Summary	137
References	139
Appendix.....	170
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Distribution of age among the study participants.....	53
Table (2):	Distribution of gender among the study participants.....	53
Table (3):	Distribution of socio-demographic features among the study participants	54
Table (4):	Distribution of family monthly income and spending among the study participants	55
Table (5):	Distribution of usual source of health care among the study participants	55
Table (6):	Distribution of duration of diabetes among the study participants	56
Table (7):	Description of results of HbA1C and random blood glucose among the studied population.....	56
Table (8):	Distribution of diabetes related complications among the study participants.....	57
Table (9):	Distribution of history of depression among the study participants	57
Table (10):	Distribution of family history of insulin use among the study participants	58
Table (11):	Distribution of previous history of hypoglycemic events among the study participants.....	59
Table (12):	Distribution of insulin recommendation by physicians among the study participants	59
Table (13):	Insulin Treatment Appraisal Scale (ITAS) scores among the studied population.....	60
Table (14):	Distribution of response to items of Insulin Treatment Appraisal Scale (ITAS) among study participants	61

List of Tables (cont...)

Table No.	Title	Page No.
Table (15):	Distribution of response to concerns towards insulin therapy among the study participants.....	64
Table (16):	Distribution of opposition to initiate insulin therapy among the study participants by number (N) and percentage (%).....	66
Table (17):	Relation between opposition to initiate insulin and age among the study participants.....	67
Table (18):	Relation between opposition to initiate insulin and gender among the study participants.....	68
Table (19):	Relation between opposition to initiate insulin and marital status among the study participants.....	69
Table (20):	Relation between opposition to initiate insulin and residence among the study participants.....	69
Table (21):	Relation between opposition to initiate insulin and educational level among the study participants.....	70
Table (22):	Relation between opposition to initiate insulin and employment status among the study participants.....	71
Table (23):	Relation between opposition to initiate insulin and family monthly income among study participants.....	71
Table (24):	Relation between opposition to initiate insulin and family monthly spending among study participants.....	72
Table (25):	Relation between opposition to initiate insulin and usual healthcare facility among study participants.....	72

List of Tables (cont...)

Table No.	Title	Page No.
Table (26):	Relation between opposition to initiate insulin and duration of diabetes among study participants	73
Table (27):	Relation between opposition to initiate insulin and results of HbA1C & random blood glucose among study participants.....	74
Table (28):	Relation between opposition to initiate insulin and diabetes related complications among study participants	75
Table (29):	Relation between opposition to initiate insulin and history of depression among study participants	75
Table (30):	Relation between opposition to initiate insulin and family history of insulin use among study participants	76
Table (31):	Relation between opposition to initiate insulin and hypoglycemic events among study participants	77
Table (32):	Relation between opposition to initiate insulin and previous doctor's recommendation on insulin among study participants	78
Table (33):	Relation between opposition to initiate insulin and Insulin Therapy Appraisal Scale (ITAS) scores among study participants	79
Table (34):	Relation between opposition to initiate insulin and items of Insulin Treatment Appraisal Scale (ITAS) among study participants	80
Table (35):	Relation between opposition to initiate insulin and concerns towards insulin therapy among study participants	84

List of Tables (cont...)

Table No.	Title	Page No.
Table (36):	Logistic regression between opposition to start insulin therapy and other variables with adjustment of age and gender.....	86
Table (37):	Correlation between duration of the disease and Insulin Treatment Appraisal Scale (ITAS) total score.....	88
Table (38):	Significant relations between the positively stated item (Insulin improves health) and features of the study participants.....	89
Table (39):	Significant relations between the positively stated item (Insulin maintain good control of blood glucose) and features of the participants.....	90
Table (40):	Significant relations between the positively stated item (Insulin improves energy level) and features of the participants	91
Table (41):	Significant relations between the positively stated item (Insulin prevents complications of diabetes) and features of the participants	92
Table (42):	Significant relations between the negatively stated item (Insulin causes health problems such as blindness) and features of the participants	93
Table (43):	Significant relations between the negatively stated item (Insulin causes weight gain) and features of the participants.....	94
Table (44):	Significant relations between the negatively stated item (Insulin increases the risk of hypoglycemia) and features of the participants	95

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Illustrating the natural history of diabetes (progression from pre diabetes to diabetes and development of diabetes complications over time)	9
Figure (2):	Showing the top ten countries for number of people with diabetes (20 -79 years) in 2015 and 2040	12
Figure (3):	Showing increase in global diabetes health expenditure, which is less than the predicted increase in number of diabetes patients	14
Figure (4):	Showing the proportional mortality in Egypt, where diabetes accounts for 1% of total deaths	15
Figure (5):	Showing general recommendations for antihyperglycemic therapy in type 2 diabetes mellitus	20
Figure (6):	Opposition to start insulin therapy.....	66

List of Abbreviations

Abb.	Full term
<i>%</i>	<i>Percentage</i>
<i>AACE</i>	<i>American Association of Clinical Endocrinologists</i>
<i>ACE</i>	<i>American College of Endocrinology</i>
<i>ADA</i>	<i>American Diabetes Association</i>
<i>DAWN study</i>	<i>Diabetes Attitudes, Wishes, Needs study</i>
<i>DM</i>	<i>Diabetes Mellitus</i>
<i>HbA1C</i>	<i>Glycated hemoglobin</i>
<i>IDF</i>	<i>International Diabetes Federation</i>
<i>ITAS</i>	<i>Insulin Treatment Appraisal Scale</i>
<i>N</i>	<i>Number</i>
<i>OHA</i>	<i>Oral Hypoglycemic Agents</i>
<i>PIR</i>	<i>Psychological Insulin Resistance</i>
<i>RBS</i>	<i>Random Blood Sugar</i>
<i>SD</i>	<i>Standard Deviation</i>
<i>SMBG</i>	<i>Self Monitoring of Blood Glucose</i>
<i>T2DM</i>	<i>Type2 Diabetes Mellitus</i>
<i>USA</i>	<i>United States of America</i>
<i>WHO</i>	<i>World Health Organization</i>

Abstract:

Background: Despite the rapid development of new antidiabetic medications, glycemic control is not improving. One of the obstacles to diabetes management is delayed initiation of insulin therapy in poorly controlled T2DM patients.

Objectives: To measure the prevalence of insulin opposition among Egyptian type 2 diabetes patients, uncontrolled, on two or more oral hypoglycaemic combination therapy and to assess factors associated with insulin opposition.

Methodology: A cross sectional study was conducted in outpatient clinics at Ain Shams University hospitals using a purposive sample of 103 type 2 diabetic patients (on maximum tolerated oral glucose-lowering therapy, and with HbA1c $\geq 9\%$ in the last 6 months or random blood glucose $\geq 300\text{--}350$ mg/dL), using a structured interview questionnaire.

Results: About half (55.3 %) of the study sample were unwilling to start insulin in spite of poor glycemic control. Comparing unwilling and willing participants, the negatively stated items that differed significantly between the 2 groups were concern about insulin being a lifelong therapy (84.2 % vs. 43.5%), Keeping insulin as a last resort (77.2% vs. 50), belief that taking insulin is a sign that diabetes had become worse (75.4% vs. 63 %), feelings of personal failure in diabetes self-management (71.9 % vs. 63%), concerns about less flexible life (59.6 % vs. 52.2%), concerns about time & effort with daily injections (29.8% vs. 13 %) and expected harm from insulin therapy (28.1% vs. 13 %). The positively stated items that differed significantly between unwilling and willing participants were about the role of insulin in improving energy level (22.8% vs 50%), improving health (28.1% vs. 60.9%) and preventing complications of diabetes (42.1% vs. 67.4%). In univariate analysis, factors associated with lower prevalence of opposition to initiate insulin therapy included family history of insulin use, previous physicians' recommendations on insulin within the previous 6 months, history of hypoglycemic attacks and longer duration of diabetes disease. Mean total Insulin Therapy Appraisal scale (ITAS) score was higher in unwilling participants compared to those willing (unwilling 47.2 vs. willing 41.6, $p=0.000$).

Conclusions: Unwilling participants have many negative attitudes concerning initiating insulin therapy. Exploring these attitudes can help address their concerns and promote the timely initiation of insulin.

Recommendations: There should be a physicians' training program to look beyond the initial refusal to the shift to insulin therapy by assessing the knowledge of and underlying beliefs of the participants regarding insulin therapy. This will thorough patients' health education about insulin. Thus, clinicians may help their patients begin insulin treatment sooner and improve compliance, thus facilitating target glycemic control.

Keywords: insulin therapy, Diabetes mellitus, prevalence, attitudes, risk factors.

INTRODUCTION

Diabetes mellitus is one of the largest global health emergencies of the 21st century (*International Diabetes Federation, 2015*). It affects more than 415 million adults worldwide. This number is expected to surge to 642 million by 2040 (*International Diabetes Federation, 2015*). Between 2010 and 2030, number of adults with diabetes would increase by 54 % globally 20 % in developed countries and 69 % in developing countries (*Shaw et al., 2010*).

Among the top ten countries for number of people with diabetes aged 20-79 years, Egypt ranks the eighth country, with 7.8 million diabetic patients. By 2040; Egypt is expected to be the seventh country with 15.1 million diabetes patients (*International Diabetes Federation, 2015*). According to WHO 2016, the national prevalence of diabetes among total population is 16.2% (*World Health Organization, 2016*).

Diabetes is associated with complications, categorized as micro vascular or macro vascular complications (*Stolar, 2010; Fowler, 2008; Skyler, 2004*). Macro vascular complications include multiple forms of cardiovascular disease, including coronary artery diseases (CAD) and cerebro vascular diseases (CVD) (*Dokken, 2008*). Micro vascular complications include retinopathy, neuropathy and nephropathy (*Martz, 2017*).

In Egypt, Diabetes is considered the eleventh most important cause of premature mortality in Egypt. It is also the sixth most important cause of disability burden in Egypt (*Herman et al., 2012*). According to WHO 2016, Diabetes accounts for 1% of total deaths in Egypt (*World Health Organization, 2016*).

Type 2 diabetes accounts for 90–95% of all diabetes (*Diabetes Care, 2017*). It is a chronic disorder characterized by progressive deterioration of the pancreatic β cells that secrete insulin, resulting in worsening hyperglycemia over time (*Kahn et al., 2009*).

Because of the progressive nature of type 2 diabetes, patients eventually reach a stage when oral hypoglycemic agents, alone or combined, fail to achieve the required glycemic level and insulin therapy becomes essential for adequate glycemic control (*Saleem et al., 2016, Wong et al., 2011*).

The American Diabetes Association and the European Association for the Study of Diabetes identified insulin replacement therapy as a key component for effective diabetes management (*Nathan et al., 2009*). Therefore, at any stage of inadequate glycemic control, insulin can be added to either monotherapy or dual or triple therapy (*American Diabetes Association, 2016*).

Despite the increasing prevalence of diabetes and the various medications including insulin, glycemic control does not appear to be improving even in developed nations (*Davidson, 2005*). About 50% of T2DM patients with poor control did not timely start insulin and the initiation was usually three to five years after failure of oral hypoglycemic agents (*Rubino et al., 2007; Nichols et al., 2007*).

There are many factors delaying insulin initiation, including those caused by healthcare providers and its system, as well as the patients themselves (*Lee et al., 2012; Peyrot et al., 2010; Kruger and Spollett, 2009*).

Psychological insulin resistance is defined as psychological opposition to initiate insulin use (*Woudenberg et al., 2012; Wong et al., 2011; Rubino et al., 2007*), as well as to its subsequent titration (*Jenkins et al., 2011*).

Psychological insulin resistance is not a psychological disorder, but rather a term that describes a strong negative attitude towards insulin therapy (*Brod et al., 2009; Polonsky et al., 2005; Peyrot et al., 2005; Bogatean and Hâncu, 2004*). It includes misconceptions regarding insulin, emotional distress and resistance towards intensive treatment (*Brod et al., 2009; Polonsky et al., 2005; Peyrot et al., 2005; Bogatean and Hâncu, 2004*).

Thus, psychological insulin resistance can prevent patients from taking the insulin they need, cause glycemic levels to increase beyond the recommended targets and put patients at risk of developing complications (*Nathan et al., 2009; Larkin et al., 2008*).

To address this issue, a global study called Diabetes Attitudes Wishes and Needs (DAWN) study was conducted in 13 countries, where 57% of T2DM patients, who were not using insulin, were worried about starting insulin (*Peyrot et al., 2005*).

In the Western community, among insulin naïve patients, 28-39% expressed insulin opposition (*Woudenberg et al., 2012; Larkin et al., 2008; Polonsky et al., 2005*). However, higher proportion was reported by Asian studies, quoting prevalence between 51–70.6% (*Nur Azmiah et al., 2011; Wong et al., 2011*).

Therefore, it is important to assess the magnitude of, and the reasons for, opposition to insulin initiation. A better understanding of the barriers to insulin, from the patient's perspective, will assist clinicians by providing needed information that can be used for patient education (*Brod et al., 2014*).

The present study aims to measure the prevalence of opposition to initiate insulin among T2DM patients with poor